Predicting the sites of metastases from lung cancer using molecular biologic markers

Annals of Thoracic Surgery

Volumn 72, Issue 4, 2001, Pages 1144-1148

  D'Amico, Thomas A ^a   Aloia, Thomas A ^a   Moore, Mary Beth H ^a   Conlon, Debbi H ^a   Herndon II, James E ^a   Kinch, Michael S ^a   Harpole Jr , David H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN P53; UROKINASE; UROKINASE RECEPTOR; UVOMORULIN;

ARTICLE; BRAIN METASTASIS; CANCER STAGING; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGAN SPECIFICITY; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 0034779755     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(01)02979-4     Document Type: Article

References (24)

1. Cancer statistics 2000
2. Revisions in the international system for staging lung cancer
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
4. Stage I non-small cell lung cancer
5. Survival in early-stage non-small cell lung cancer
6. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small cell lung cancer?
7. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1N0M0 non-small cell lung cancer
8. Histopathologic prognostic factors in adenocarcinoma of the lung periphery less than 2 cm in diameter
9. A biological risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers
10. Molecular biologic substaging in patients with stage I non-small cell lung cancer: Risk stratification according to gender and histologic subtype
11. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer
12. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
13. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: Clinical implications
14. Molecular and pathologic markers in stage I non-small cell carcinoma of the lung
15. Overexpression of the EphA2 tyrosine kinase in prostate cancer
16. The role of E-cadherin-catenin complex: More than an intracellular glue
17. The urokinase-type plasminogen activator system in resected non-small cell lung cancer
18. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
19. Molecular biologic markers predict the development of cerebral metastases in patients with stage I non-small cell lung cancer
20. Resection of brain metastases from non-small cell lung carcinoma. Result of therapy
21. A randomized trial of surgery in the treatment of single metastases to the brain
22. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission
23. Prophylactic cranial irradiation in locally advanced non-small cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects